Citius Oncology, Inc.
Citius Oncology, Inc. CTOR Peers
See (CTOR) competitors and their performances in Stock Market.
Peer Comparison Table: Drug Manufacturers - General Industry
Detailed financial metrics including price, market cap, P/E ratio, and more.
| Symbol | Price | Change % | Market Cap | P/E Ratio | EPS | Dividend Yield |
|---|---|---|---|---|---|---|
| CTOR | $0.89 | +0.45% | 64M | -2.35 | -$0.38 | N/A |
| LLY | $719.10 | -0.84% | 681.5B | 58.65 | $12.26 | +0.78% |
| AZN | $70.38 | -0.82% | 436.4B | 28.38 | $2.48 | +2.19% |
| JNJ | $152.44 | -0.53% | 366.8B | 16.94 | $9.00 | +3.29% |
| ABBV | $183.03 | -1.45% | 323.3B | 77.88 | $2.35 | +3.48% |
| NVO | $68.61 | -2.60% | 307.2B | 19.16 | $3.58 | +2.35% |
| NVS | $111.86 | -1.20% | 220.9B | 17.45 | $6.41 | +3.57% |
| MRK | $76.16 | -1.85% | 191.2B | 11.07 | $6.88 | +4.15% |
| AMGN | $278.40 | -0.38% | 149.7B | 25.36 | $10.98 | +3.33% |
| GILD | $108.44 | -0.60% | 134.9B | 14.01 | $7.74 | +2.87% |
Stock Comparison
CTOR vs LLY Comparison
CTOR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CTOR stands at 64M. In comparison, LLY has a market cap of 681.5B. Regarding current trading prices, CTOR is priced at $0.89, while LLY trades at $719.10.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CTOR currently has a P/E ratio of -2.35, whereas LLY's P/E ratio is 58.65. In terms of profitability, CTOR's ROE is -0.15%, compared to LLY's ROE of +0.77%. Regarding short-term risk, CTOR is more volatile compared to LLY. This indicates potentially higher risk in terms of short-term price fluctuations for CTOR.
CTOR vs AZN Comparison
CTOR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CTOR stands at 64M. In comparison, AZN has a market cap of 436.4B. Regarding current trading prices, CTOR is priced at $0.89, while AZN trades at $70.38.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CTOR currently has a P/E ratio of -2.35, whereas AZN's P/E ratio is 28.38. In terms of profitability, CTOR's ROE is -0.15%, compared to AZN's ROE of +0.19%. Regarding short-term risk, CTOR is more volatile compared to AZN. This indicates potentially higher risk in terms of short-term price fluctuations for CTOR.
CTOR vs JNJ Comparison
CTOR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CTOR stands at 64M. In comparison, JNJ has a market cap of 366.8B. Regarding current trading prices, CTOR is priced at $0.89, while JNJ trades at $152.44.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CTOR currently has a P/E ratio of -2.35, whereas JNJ's P/E ratio is 16.94. In terms of profitability, CTOR's ROE is -0.15%, compared to JNJ's ROE of +0.30%. Regarding short-term risk, CTOR is more volatile compared to JNJ. This indicates potentially higher risk in terms of short-term price fluctuations for CTOR.
CTOR vs ABBV Comparison
CTOR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CTOR stands at 64M. In comparison, ABBV has a market cap of 323.3B. Regarding current trading prices, CTOR is priced at $0.89, while ABBV trades at $183.03.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CTOR currently has a P/E ratio of -2.35, whereas ABBV's P/E ratio is 77.88. In terms of profitability, CTOR's ROE is -0.15%, compared to ABBV's ROE of +0.96%. Regarding short-term risk, CTOR is more volatile compared to ABBV. This indicates potentially higher risk in terms of short-term price fluctuations for CTOR.
CTOR vs NVO Comparison
CTOR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CTOR stands at 64M. In comparison, NVO has a market cap of 307.2B. Regarding current trading prices, CTOR is priced at $0.89, while NVO trades at $68.61.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CTOR currently has a P/E ratio of -2.35, whereas NVO's P/E ratio is 19.16. In terms of profitability, CTOR's ROE is -0.15%, compared to NVO's ROE of +0.81%. Regarding short-term risk, CTOR is more volatile compared to NVO. This indicates potentially higher risk in terms of short-term price fluctuations for CTOR.
CTOR vs NVS Comparison
CTOR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CTOR stands at 64M. In comparison, NVS has a market cap of 220.9B. Regarding current trading prices, CTOR is priced at $0.89, while NVS trades at $111.86.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CTOR currently has a P/E ratio of -2.35, whereas NVS's P/E ratio is 17.45. In terms of profitability, CTOR's ROE is -0.15%, compared to NVS's ROE of +0.31%. Regarding short-term risk, CTOR is more volatile compared to NVS. This indicates potentially higher risk in terms of short-term price fluctuations for CTOR.
CTOR vs MRK Comparison
CTOR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CTOR stands at 64M. In comparison, MRK has a market cap of 191.2B. Regarding current trading prices, CTOR is priced at $0.89, while MRK trades at $76.16.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CTOR currently has a P/E ratio of -2.35, whereas MRK's P/E ratio is 11.07. In terms of profitability, CTOR's ROE is -0.15%, compared to MRK's ROE of +0.38%. Regarding short-term risk, CTOR is more volatile compared to MRK. This indicates potentially higher risk in terms of short-term price fluctuations for CTOR.
CTOR vs AMGN Comparison
CTOR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CTOR stands at 64M. In comparison, AMGN has a market cap of 149.7B. Regarding current trading prices, CTOR is priced at $0.89, while AMGN trades at $278.40.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CTOR currently has a P/E ratio of -2.35, whereas AMGN's P/E ratio is 25.36. In terms of profitability, CTOR's ROE is -0.15%, compared to AMGN's ROE of +0.93%. Regarding short-term risk, CTOR is more volatile compared to AMGN. This indicates potentially higher risk in terms of short-term price fluctuations for CTOR.
CTOR vs GILD Comparison
CTOR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CTOR stands at 64M. In comparison, GILD has a market cap of 134.9B. Regarding current trading prices, CTOR is priced at $0.89, while GILD trades at $108.44.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CTOR currently has a P/E ratio of -2.35, whereas GILD's P/E ratio is 14.01. In terms of profitability, CTOR's ROE is -0.15%, compared to GILD's ROE of +0.32%. Regarding short-term risk, CTOR is more volatile compared to GILD. This indicates potentially higher risk in terms of short-term price fluctuations for CTOR.
CTOR vs PFE Comparison
CTOR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CTOR stands at 64M. In comparison, PFE has a market cap of 131.8B. Regarding current trading prices, CTOR is priced at $0.89, while PFE trades at $23.18.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CTOR currently has a P/E ratio of -2.35, whereas PFE's P/E ratio is 16.55. In terms of profitability, CTOR's ROE is -0.15%, compared to PFE's ROE of +0.09%. Regarding short-term risk, CTOR is more volatile compared to PFE. This indicates potentially higher risk in terms of short-term price fluctuations for CTOR.
CTOR vs SNY Comparison
CTOR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CTOR stands at 64M. In comparison, SNY has a market cap of 126.7B. Regarding current trading prices, CTOR is priced at $0.89, while SNY trades at $51.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CTOR currently has a P/E ratio of -2.35, whereas SNY's P/E ratio is 18.37. In terms of profitability, CTOR's ROE is -0.15%, compared to SNY's ROE of +0.08%. Regarding short-term risk, CTOR is more volatile compared to SNY. This indicates potentially higher risk in terms of short-term price fluctuations for CTOR.
CTOR vs BMY Comparison
CTOR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CTOR stands at 64M. In comparison, BMY has a market cap of 95.6B. Regarding current trading prices, CTOR is priced at $0.89, while BMY trades at $46.98.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CTOR currently has a P/E ratio of -2.35, whereas BMY's P/E ratio is 17.53. In terms of profitability, CTOR's ROE is -0.15%, compared to BMY's ROE of +0.32%. Regarding short-term risk, CTOR is more volatile compared to BMY. This indicates potentially higher risk in terms of short-term price fluctuations for CTOR.
CTOR vs CELG-RI Comparison
CTOR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CTOR stands at 64M. In comparison, CELG-RI has a market cap of 95.3B. Regarding current trading prices, CTOR is priced at $0.89, while CELG-RI trades at $0.03.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CTOR currently has a P/E ratio of -2.35, whereas CELG-RI's P/E ratio is N/A. In terms of profitability, CTOR's ROE is -0.15%, compared to CELG-RI's ROE of +0.32%. Regarding short-term risk, CTOR is less volatile compared to CELG-RI. This indicates potentially lower risk in terms of short-term price fluctuations for CTOR.
CTOR vs GSK Comparison
CTOR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CTOR stands at 64M. In comparison, GSK has a market cap of 79.5B. Regarding current trading prices, CTOR is priced at $0.89, while GSK trades at $39.20.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CTOR currently has a P/E ratio of -2.35, whereas GSK's P/E ratio is 19.03. In terms of profitability, CTOR's ROE is -0.15%, compared to GSK's ROE of +0.22%. Regarding short-term risk, CTOR is more volatile compared to GSK. This indicates potentially higher risk in terms of short-term price fluctuations for CTOR.
CTOR vs HZNP Comparison
CTOR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CTOR stands at 64M. In comparison, HZNP has a market cap of 26.6B. Regarding current trading prices, CTOR is priced at $0.89, while HZNP trades at $116.30.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CTOR currently has a P/E ratio of -2.35, whereas HZNP's P/E ratio is 61.86. In terms of profitability, CTOR's ROE is -0.15%, compared to HZNP's ROE of +0.11%. Regarding short-term risk, CTOR is more volatile compared to HZNP. This indicates potentially higher risk in terms of short-term price fluctuations for CTOR.
CTOR vs BIIB Comparison
CTOR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CTOR stands at 64M. In comparison, BIIB has a market cap of 18.7B. Regarding current trading prices, CTOR is priced at $0.89, while BIIB trades at $127.53.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CTOR currently has a P/E ratio of -2.35, whereas BIIB's P/E ratio is 12.60. In terms of profitability, CTOR's ROE is -0.15%, compared to BIIB's ROE of +0.09%. Regarding short-term risk, CTOR is more volatile compared to BIIB. This indicates potentially higher risk in terms of short-term price fluctuations for CTOR.
CTOR vs GRFS Comparison
CTOR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CTOR stands at 64M. In comparison, GRFS has a market cap of 6.8B. Regarding current trading prices, CTOR is priced at $0.89, while GRFS trades at $8.18.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CTOR currently has a P/E ratio of -2.35, whereas GRFS's P/E ratio is 31.46. In terms of profitability, CTOR's ROE is -0.15%, compared to GRFS's ROE of +0.03%. Regarding short-term risk, CTOR is more volatile compared to GRFS. This indicates potentially higher risk in terms of short-term price fluctuations for CTOR.
CTOR vs OGN Comparison
CTOR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CTOR stands at 64M. In comparison, OGN has a market cap of 2.4B. Regarding current trading prices, CTOR is priced at $0.89, while OGN trades at $9.15.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CTOR currently has a P/E ratio of -2.35, whereas OGN's P/E ratio is 3.18. In terms of profitability, CTOR's ROE is -0.15%, compared to OGN's ROE of +1.82%. Regarding short-term risk, CTOR is more volatile compared to OGN. This indicates potentially higher risk in terms of short-term price fluctuations for CTOR.
CTOR vs SCLX Comparison
CTOR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CTOR stands at 64M. In comparison, SCLX has a market cap of 36.5M. Regarding current trading prices, CTOR is priced at $0.89, while SCLX trades at $5.25.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CTOR currently has a P/E ratio of -2.35, whereas SCLX's P/E ratio is -0.34. In terms of profitability, CTOR's ROE is -0.15%, compared to SCLX's ROE of +0.36%. Regarding short-term risk, CTOR is less volatile compared to SCLX. This indicates potentially lower risk in terms of short-term price fluctuations for CTOR.
CTOR vs SCLXW Comparison
CTOR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CTOR stands at 64M. In comparison, SCLXW has a market cap of 35.3M. Regarding current trading prices, CTOR is priced at $0.89, while SCLXW trades at $0.09.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CTOR currently has a P/E ratio of -2.35, whereas SCLXW's P/E ratio is N/A. In terms of profitability, CTOR's ROE is -0.15%, compared to SCLXW's ROE of +0.36%. Regarding short-term risk, CTOR is more volatile compared to SCLXW. This indicates potentially higher risk in terms of short-term price fluctuations for CTOR.
CTOR vs MIRA Comparison
CTOR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CTOR stands at 64M. In comparison, MIRA has a market cap of 22.6M. Regarding current trading prices, CTOR is priced at $0.89, while MIRA trades at $1.34.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CTOR currently has a P/E ratio of -2.35, whereas MIRA's P/E ratio is -2.84. In terms of profitability, CTOR's ROE is -0.15%, compared to MIRA's ROE of -3.41%. Regarding short-term risk, CTOR is more volatile compared to MIRA. This indicates potentially higher risk in terms of short-term price fluctuations for CTOR.
CTOR vs SRXH Comparison
CTOR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CTOR stands at 64M. In comparison, SRXH has a market cap of 6.7M. Regarding current trading prices, CTOR is priced at $0.89, while SRXH trades at $0.58.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CTOR currently has a P/E ratio of -2.35, whereas SRXH's P/E ratio is N/A. In terms of profitability, CTOR's ROE is -0.15%, compared to SRXH's ROE of -0.50%. Regarding short-term risk, CTOR is more volatile compared to SRXH. This indicates potentially higher risk in terms of short-term price fluctuations for CTOR.
CTOR vs CRXT Comparison
CTOR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CTOR stands at 64M. In comparison, CRXT has a market cap of 0. Regarding current trading prices, CTOR is priced at $0.89, while CRXT trades at $0.05.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CTOR currently has a P/E ratio of -2.35, whereas CRXT's P/E ratio is -0.02. In terms of profitability, CTOR's ROE is -0.15%, compared to CRXT's ROE of -4.63%. Regarding short-term risk, CTOR is less volatile compared to CRXT. This indicates potentially lower risk in terms of short-term price fluctuations for CTOR.